[acb-diabetics] diabetes vaccine seen in near future

[Patricia LaFrance-Wolf]

Diabetes Vaccine Possible This Decade, Says Report

 

In the not-too-distant future we could see diabetes, the seventh leading
cause of death in the U.S., treated with a vaccine. Several vaccine
candidates

are in the pipeline, creating a possible $2.4 billion market for diabetes
vaccine products by 2020.

 

Advertisement 

 

Click here to find out more! frame

 

Flash movie start

Flash movie end

Click here to find out more! frame end

 

Type 1 diabetes currently afflicts 35,000 people in the U.S. and about
700,000 people worldwide each year. Type 2 diabetes affects more than 16
million

Americans and over 200 million people worldwide. 

 

Currently, other than a humanized anti-CD3 antibody with considerable side
effects, there is no other means to reverse new-onset Type 1 diabetes.
People

with Type 2 diabetes must control their blood sugar levels with diet and
exercise, and approximately 78% also take prescription medications to help
control

their diabetes. However, they remain at risk for a large number of
associated conditions including foot ulcers, heart disease, kidney failure,
and various

skin conditions.

 

There are at least seven diabetes vaccine candidates in development. Most
are in Phase I testing and address Type 1 diabetes. But one being developed
by

the Swedish company Diamyd Medical is currently in a global Phase III trial,
which includes 640 children and adolescents newly diagnosed with Type 1
diabetes.

The purpose of the Phase III trial is to confirm and evaluate the ability of
the Diamyd vaccine to arrest or slow the autoimmune destruction of the
body's

insulin-producing cells, thereby preserving the body's own ability to
produce insulin. Initial analysis of data from the Phase II trial showed
that patients

treated with the Diamyd vaccine early after diagnosis have a clearly better
diabetes status compared to the corresponding placebo group four years after

the injections. 

 

In a special report, Kalorama predicts a $100 million market from diabetes
vaccines by 2012 as the first product currently in Phase III trials enters
the

market, with growth amounting to $2.4 billion by 2020 as other products
reach market. 

 

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://www.acb.org/pipermail/acb-diabetics/attachments/20100323/31aa3bff/attachment.htm>